🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522512-16-00
Completed Phase I

Phase 1 trial of valemetostat and darolutamide in mCRPC

2025-522512-16-00 · tracked via the Priya Life Science EU tracker
Sponsor
Daiichi Sankyo Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
18/03/2026
Enrollment target
13
Sites
Ireland, Spain, France

Condition studied

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Eligibility

Age group
18-64 years, 65+ years
Sex
Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522512-16-00 on CTIS ↗ ← All trials in the EU